Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Lupus/Nephritis -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (8)	4/17/2001 3:36:45 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 95

CTLA4 Ig. Mention in same link. Didn't know about PDLI's efforts. (No obviously mentioned in 10K or home page, is this accurate?) Costimulatory blockers represent the most intriguing new strategy for lupus treatment, Decision Resources says in a report. The agents, which are in early stages of development, include Bristol-Myers Squibb’s humanized antibody BMS-188667 and Protein Design Labs’ CTLA4-Ig antibody. The most fundamental market need is a better understanding of lupus etiology to guide development of therapeutics with increased efficacy and reduced side effects.